MB-CART-FolR1

MB-CART-FolR1 is a **folate receptor alpha-directed autologous CAR-T cell therapy** being developed by Miltenyi Biotec and Miltenyi Biomedicine for **ovarian cancer**. Publicly available preclinical data describe it as a FOLR1-targeted CAR-T program generated from genetically engineered T cells expressing an anti-FOLR1 chimeric antigen receptor incorporating a **CD8alpha transmembrane domain**, **4-1BB costimulatory domain**, and **CD3 zeta signaling domain**; the development work selected a lead construct from multiple candidates for potential clinical translation. The intended mechanism is selective recognition of **folate receptor alpha-expressing tumor cells** followed by T-cell activation, cytokine release, cytolytic killing, and expansion/persistence in vivo. As of publicly available evidence, MB-CART-FolR1 appears to be a **preclinical solid-tumor CAR-T asset** with ovarian cancer as the clearest disclosed indication.